Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for a new cardiovascular risk reduction claim, as it faces increased competition from Novo Nordisk.

Trulicity’s performance was a big positive for Lilly however, as there had been speculation that it might start to slow down thanks to the challenge from Ozempic – which has outperformed it in ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46 th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce ...

Lilly’s new products also contributed to sales growth. Trulicity sales continued to decline in the quarter. Lilly maintained its sales guidance for 2025 while lowering its earnings expectations ...

Medicare Part D plans and some Part C plans may cover Trulicity (dulaglutide) for diabetes, but the exact coverage depends on the plan. Such plans will only cover this drug for weight loss in ...

Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer ... among other treatments. It also makes diabetes drugs Trulicity, Humalog and Jardiance, among ...

Lilly beat fourth-quarter estimates for earnings as well as sales. Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound ... Total Diabetes care rose 17% and Obesity care ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. After a thorough review ...